Evidence map›Paper›PMID 29594983›Full record

ArticleJournal of neurovirology2018

Persistent EcoHIV infection induces nigral degeneration in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-intoxicated mice.

Katherine E Olson, Aditya N Bade, Krista L Namminga, Mary Jane Potash, R Lee Mosley, Larisa Y Poluektova, David J Volsky, Howard E Gendelman

Abstract read
In one paragraph

Article in Journal of neurovirology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. COVID-19 Infection Enhances Susceptibility to Oxidative Stress-Induced Parkinsonism.Movement disorders : official journal of the Movement Disorder Society · 2022
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Katherine E OlsonDepartment of Pharmacology and Experimental Neuroscience, Center for Neurodegenerative Disorders, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Aditya N BadeDepartment of Pharmacology and Experimental Neuroscience, Center for Neurodegenerative Disorders, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Krista L NammingaDepartment of Pharmacology and Experimental Neuroscience, Center for Neurodegenerative Disorders, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Mary Jane PotashDepartment of Medicine, Infectious Diseases Division, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
R Lee MosleyDepartment of Pharmacology and Experimental Neuroscience, Center for Neurodegenerative Disorders, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Larisa Y PoluektovaDepartment of Pharmacology and Experimental Neuroscience, Center for Neurodegenerative Disorders, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
David J VolskyDepartment of Medicine, Infectious Diseases Division, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
Howard E GendelmanDepartment of Pharmacology and Experimental Neuroscience, Center for Neurodegenerative Disorders, University of Nebraska Medical Center, Omaha, NE, 68198, USA. hegendel@unmc.edu.
University of Nebraska Medical Center · USIcahn School of Medicine at Mount Sinai · US

Funding

Therapeutics Core (Page 286)P30MH062261 · NIMH · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BUCH, SHILPA J., FOX, HOWARD S · 2000 to 2021
$37.7M
Targeted Neuro Protection of HIV-1 Associated Neurologic DiseaseP01MH064570 · NIMH · UNIVERSITY OF ROCHESTER · PI GELBARD, HARRIS A · 2001 to 2014
$19.4M
Pharmacokinetics and Drug-Drug InteractionsP01DA028555 · NIDA · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BOSKA, MICHAEL DOUGLAS · 2010 to 2019
$16.8M
Neuroprotective Immunity and HIV DementiaR01NS034239 · NINDS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Howard E Gendelman, R Lee Mosley · 1995 to 2026
$12.3M
Proteomics CoreP01NS043985 · NINDS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BOSKA, MICHAEL DOUGLAS · 2003 to 2012
$11.8M
Effect of buprenorphine on monocytes in the context of neuroAids and opioid abuseR01DA041931 · NIDA · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI Joan Weinberger Berman, JENNIFER L KELSCHENBACH · 2017 to 2026
$7.4M
Toward a Mouse Model of HIV-1 Infection and Drug AddictionR01DA017618 · NIDA · ST. LUKE'S-ROOSEVELT INST FOR HLTH SCIS · PI POTASH, MARY JANE, VOLSKY, DAVID J · 2004 to 2015
$6.2M
Nanomedicine and NeuroAIDSR01NS036126 · NINDS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI GENDELMAN, HOWARD E · 1997 to 2017
$5.7M
Threshold of Cognitive Impairment after HIV Infection: Effect of MorphineR01DA037611 · NIDA · ST. LUKE'S-ROOSEVELT INST FOR HLTH SCIS · PI VOLSKY, DAVID J · 2014 to 2018
$4.0M
Toward control of HIV neuropathogenesis by innate immunityR01NS094146 · NINDS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI POTASH, MARY JANE, VOLSKY, DAVID J · 2016 to 2020
$3.6M
Combined Molecular Excision Therapy (CMET) for Eliminating HIV-1R01MH115860 · NIMH · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI GENDELMAN, HOWARD E · 2017 to 2021
$3.5M
CNS Reservoirs of HIV in a Mouse Model of HIV Infection and Cognitive Impairment:R01MH104145 · NIMH · ST. LUKE'S-ROOSEVELT INST FOR HLTH SCIS · PI VOLSKY, DAVID J · 2014 to 2018
$3.4M
NIA NIH HHS R01 AG043540NIDA NIH HHS P01 DA028555NIDA NIH HHS R01 DA017618NIDA NIH HHS R01 DA037611NIDA NIH HHS R01 DA041931NIDA NIH HHS R03 DA022169NIH HHS AG043540NIH HHS DA028555NIH HHS DA037611NIH HHS MH062261NIH HHS MH064570NIH HHS MH086372NIH HHS MH104145NIH HHS NS034239NIH HHS NS036126NIH HHS NS043985NIH HHS NS094146NIH HHS R24 OD018546NIMH NIH HHS P01 MH064570NIMH NIH HHS P30 MH062261NIMH NIH HHS R01 MH083627NIMH NIH HHS R01 MH104145NIMH NIH HHS R01 MH115860NIMH NIH HHS R21 MH086372NINDS NIH HHS P01 NS043985NINDS NIH HHS R01 NS034239NINDS NIH HHS R01 NS036126NINDS NIH HHS R01 NS094146NINDS NIH HHS R03 NS117157NINDS NIH HHS R21 NS054580NINDS NIH HHS R21 NS061646NINDS NIH HHS R37 NS036126
6 · The paper itself

Abstract

The widespread use of antiretroviral therapy for treatment of human immunodeficiency virus (HIV) infections has dramatically improved the quality and duration of life for HIV-positive individuals. Despite this success, HIV persists for the life of an infected person in tissue reservoirs including the nervous system. Thus, whether HIV exacerbates age-related brain disorders such as Parkinson's disease (PD) is of concern. In support of this idea, HIV infection can be associated with motor and gait abnormalities that parallel late-stage manifestations of PD including dopaminergic neuronal loss. With these findings in hand, we investigated whether viral infection could affect nigrostriatal degeneration or exacerbate chemically induced nigral degeneration. We now demonstrate an additive effect of EcoHIV on dopaminergic neuronal loss and neuroinflammation induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication. HIV-1-infected humanized mice failed to recapitulate these EcoHIV results suggesting species-specific neural signaling. The results demonstrate a previously undefined EcoHIV-associated neurodegenerative response that may be used to model pathobiological aspects of PD.

Indexed as

AnimalsHIV-1HIV InfectionsHumansMiceMice, Inbred C57BLMPTP PoisoningNerve DegenerationSubstantia Nigra1-methyl-4-phenyl-1,2,3,6-tetrahydropyridineCentral nervous systemEcoHIVHuman immunodeficiency virusParkinson’s disease

Identifiers

PMID29594983
PMCPMC6105545
OpenAlexW2795301150

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.